Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in March-April
Van Lanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage ...
VanLanschot Kempen Life Sciences Conference MADRID, Spain and CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Oryzon ...
4d
Clinical Trials Arena on MSNViiV to trial twice-yearly HIV antibody dosing after Phase IIb successThe company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s ...
GOTHENBURG, SE / ACCESS Newswire / March 12, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, March 12, 2025 - IRLAB Therapeutics AB , a company discovering and developing novel ...
Data from a mid-stage study shows that treatment with Trevi's experimental drug reduced patients' 24-hour cough frequency by 57% over placebo.
The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results